Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 11/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 10/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.35 |
| ▸ | QPCT | Q16769 | 1/20 | 0.35 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.35 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1535118 | 0.76 | CYP19A1 (0.57) | CYP19A1CYP11B1CYP11B2CYP1A2POLB | |
| SCHEMBL160611 | 0.75 | CYP11B1 (0.69) | CYP19A1CYP11B1CYP11B2CYP1A2POLB | |
| SCHEMBL11372093 | 0.74 | CYP19A1 (0.59) | CYP19A1CYP11B1CYP11B2POLBMAPT | |
| SCHEMBL14549033 | 0.73 | CYP19A1 (0.49) | CYP19A1CYP11B1CYP11B2CYP1A2POLB | |
| SCHEMBL2286797 | 0.72 | CYP11B1 (0.64) | CYP19A1CYP11B1CYP11B2CYP2A6 | |
| SCHEMBL27605964 | 0.67 | CYP19A1 (0.67) | CYP19A1CYP3A4 | |
| SCHEMBL932804 | 0.67 | HTR1A (0.37) | CYP19A1POLB | |
| SCHEMBL1571252 | 0.67 | CYP19A1 (0.67) | CYP19A1 | |
| SCHEMBL59637 | 0.64 | — | — | |
| SCHEMBL60705 | 0.64 | HRH3 (0.66) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120329784-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC | 2012-12-27 | — | — | US | disclosed |
| EP-2523559-A1 | COMPOUNDS AND METHODS | GlaxoSmithKline LLC (US) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011088027-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088031-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329784-A1 | COMPOUNDS AND METHODS | RB1, DHFR, NQO1 | CYP19A1 30/4885CYP11B1 323/4885CYP11B2 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.